News, Events, and Updates

Keytruda Approved for the Adjuvant Treatment of Patients With Stage III Melanoma
News 02/15/2019

Keytruda Approved for the Adjuvant Treatment of Patients With Stage III Melanoma

Merck announced that the Food and Drug Administration (FDA) has approved Keytruda(pembrolizumab) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. This marks the first approval for Keytruda in the adjuvant setting and the fourth approval for its use in skin cancers.

Please keep me informed.

Receive comprehensive, breaking news about melanoma, research, legislation, and events.

  • This field is for validation purposes and should be left unchanged.